Key Drivers
- Very strong liquidity
- High margins
- Large SG&A
AIAI Summary
INMD has shifted from a high‑growth install narrative to a cash‑rich, buyback‑focused compounder—expect muted near‑term revenue and margin expansion unless management executes accretive buybacks and consumables adoption meaningfully accelerates, while the primary downside is clinic financing weakness and execution risk on new product rollouts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very strong liquidity
- •High margins
- •Large SG&A
INMD is a low‑risk, cash‑rich business with very strong liquidity and margins, conservative leverage and solid free cash flow, but constrained by high SG&A and modest asset turnover.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-SMA trading
- •Support testing risk
Price has slid from a Feb 20 peak of $15.22 into a short-term downtrend, trading just below its last-month SMA (~$13.64) at $13.53 and risking a retest of support near $12.76 unless buyers push back above $14.05–$15.22.
Clear peak at $15.22 on 2026-02-20 followed by steady drift lower into
Sentiment & News
Key News Insights:
- •Committee ended
- •10% buyback
- •Neutral analyst
InMode ended its sale review as inadequate, continued investor outreach, and authorized a ~10% share buyback while analyst sentiment remained neutral and shares showed mixed reactions.
The buyback and outreach should provide support and signal management action, but the lack of a deal keeps upside limited under prevailing neutral analyst sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings